B. Nordlinger, H. Sorbye, B. Glimelius, G. J. Poston, P. M. Schlag et al., Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial, Lancet Oncol, vol.14, p.24120480, 2013.

C. Tournigand, T. André, F. Bonnetain, B. Chibaudel, G. Lledo et al., Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial, J Clin Oncol Off J Am Soc Clin Oncol, vol.30, pp.3353-3360, 2012.

A. De-gramont, A. Figer, M. Seymour, M. Homerin, A. Hmissi et al., Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer, J Clin Oncol Off J Am Soc Clin Oncol, vol.18, pp.2938-2947, 2000.

N. Kitada, K. Takara, T. Minegaki, C. Itoh, M. Tsujimoto et al., Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines, Cancer Chemother Pharmacol, vol.62, pp.577-584, 2008.

S. Zhang, K. S. Lovejoy, J. E. Shima, L. L. Lagpacan, Y. Shu et al., Organic cation transporters are determinants of oxaliplatin cytotoxicity, Cancer Res, vol.66, pp.8847-8857, 2006.

A. Yonezawa, S. Masuda, S. Yokoo, T. Katsura, and K. Inui, Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family), J Pharmacol Exp Ther, vol.319, pp.879-886, 2006.

S. Yokoo, S. Masuda, A. Yonezawa, T. Terada, T. Katsura et al., Significance of organic cation transporter 3 (SLC22A3) expression for the cytotoxic effect of oxaliplatin in colorectal cancer, Drug Metab Dispos Biol Fate Chem, vol.36, pp.2299-2306, 2008.

P. Noordhuis, A. C. Laan, K. Van-de-born, N. Losekoot, I. Kathmann et al., Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines, Biochem Pharmacol, vol.76, pp.53-61, 2008.

A. Tashiro, S. Tatsumi, R. Takeda, A. Naka, H. Matsuoka et al., High expression of organic anion transporter 2 and organic cation transporter 2 is an independent predictor of good outcomes in patients with metastatic colorectal cancer treated with FOLFOX-based chemotherapy, Am J Cancer Res, vol.4, pp.528-536, 2014.

S. Tatsumi, H. Matsuoka, Y. Hashimoto, K. Hatta, K. Maeda et al., Organic cation transporter 2 and tumor budding as independent prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, Int J Clin Exp Pathol, vol.7, pp.204-212, 2014.

E. Martinez-balibrea, A. Martínez-cardús, E. Musulén, A. Ginés, J. L. Manzano et al., Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy, Int J Cancer J Int Cancer, vol.124, pp.2905-2910, 2009.

Y. Ma, J. Peng, P. Zhang, W. Liu, L. Huang et al., Immunohistochemical analysis revealed CD34 and Ki67 protein expression as significant prognostic factors in colorectal cancer, Med Oncol Northwood Lond Engl, vol.27, pp.304-309, 2010.

R. Pirker, J. R. Pereira, J. Von-pawel, M. Krzakowski, R. Ramlau et al., EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study, Lancet Oncol, vol.13, issue.11, pp.70318-70325, 2012.

P. A. Harris, R. Taylor, R. Thielke, J. Payne, N. Gonzalez et al., Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support, J Biomed Inform, vol.42, pp.377-381, 2009.

C. Jennison, Group sequential methods with applications to clinical trials, 2000.

, Oxaliplatin Transporters and FOLFOX-4 Adjuvant Chemotherapy PLOS ONE, 2016.

P. Ray, L. Manach, Y. Riou, B. Houle, and T. T. , Statistical evaluation of a biomarker, Anesthesiology, vol.112, pp.1023-1040, 2010.

G. E. Noether, Sample Size Determination for Some Common Nonparametric Tests, J Am Stat Assoc, vol.82, pp.645-647, 1987.

R. J. Feise, Do multiple outcome measures require p-value adjustment, BMC Med Res Methodol, vol.2, issue.8, 2002.

J. Cohen, A power primer, Psychol Bull, vol.112, pp.155-159, 1992.

S. C. Tang, J. Hendrikx, J. H. Beijnen, and A. H. Schinkel, Genetically modified mouse models for oral drug absorption and disposition, Curr Opin Pharmacol, vol.13, pp.853-858, 2013.

A. Mulgaonkar, J. Venitz, D. Gründemann, and D. H. Sweet, Human organic cation transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as disposition pathways for fluoroquinolone antimicrobials, Antimicrob Agents Chemother, vol.57, pp.2705-2711, 2013.

T. K. Han, R. S. Everett, W. R. Proctor, C. M. Ng, C. L. Costales et al., Organic cation transporter 1 (OCT1/mOct1) is localized in the apical membrane of Caco-2 cell monolayers and enterocytes, Mol Pharmacol, vol.84, pp.182-189, 2013.

J. Müller, K. S. Lips, L. Metzner, R. Neubert, H. Koepsell et al., Drug specificity and intestinal membrane localization of human organic cation transporters (OCT), Biochem Pharmacol, vol.70, pp.1851-1860, 2005.

J. W. Jonker, E. Wagenaar, C. A. Mol, M. Buitelaar, H. Koepsell et al., Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1 [Slc22a1]) gene, Mol Cell Biol, vol.21, pp.5471-5477, 2001.

N. Lee, H. Duan, M. F. Hebert, C. J. Liang, K. M. Rice et al., Taste of a pill: organic cation transporter-3 (OCT3) mediates metformin accumulation and secretion in salivary glands, J Biol Chem, vol.289, pp.27055-27064, 2014.

J. Y. Douillard, D. Cunningham, A. D. Roth, M. Navarro, R. D. James et al., Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial, Lancet Lond Engl, vol.355, pp.1041-1047, 2000.

L. B. Saltz, J. V. Cox, C. Blanke, L. S. Rosen, L. Fehrenbacher et al., Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group, N Engl J Med, vol.343, pp.905-914, 2000.

S. Gupta, G. Wulf, M. Henjakovic, H. Koepsell, G. Burckhardt et al., Human organic cation transporter 1 is expressed in lymphoma cells and increases susceptibility to irinotecan and paclitaxel, J Pharmacol Exp Ther, vol.341, pp.16-23, 2012.

M. V. Tzvetkov, S. Pereira, J. N. Meineke, I. Saadatmand, A. R. Stingl et al., Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration, Biochem Pharmacol, vol.86, pp.666-678, 2013.

A. T. Nies, U. Hofmann, C. Resch, E. Schaeffeler, M. Rius et al., Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs), PLoS ONE, vol.6, p.22163, 2011.

L. C. Phua, M. Mal, P. K. Koh, P. Y. Cheah, E. Chan et al., Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapy, Cancer Chemother Pharmacol, vol.71, pp.817-823, 2013.

D. J. Gallagher and N. Kemeny, Metastatic colorectal cancer: from improved survival to potential cure, Oncology, vol.78, pp.237-248, 2010.

T. M. Pawlik, C. R. Scoggins, D. Zorzi, E. K. Abdalla, A. Andres et al., Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases, Ann Surg, vol.241, pp.715-722, 2005.